← All trials
NCT05902988
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Jun 15, 2023
- Last posted
- Oct 31, 2023
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Volastra Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Esophageal Neoplasms
- Neoplasms
- Ovarian Diseases
- Ovarian Neoplasms
- Stomach Neoplasms
- Uterine Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Chromosomal Instability
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.